APO Research
Talk to an analyst

APO RESEARCH · REPORT

IBS Treatment

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global IBS Treatment Market Analysis and Forecast 2026-2032

20 December 2025219 pages

Choose your research edition.

Industry ResearchIBS Treatment Industry Research Report 2026145 pages · $2,950 USDIndustry Growth & TrendsGlobal IBS Treatment Industry Growth and Trends Forecast to 2032120 pages · $3,450 USDMarket StructureGlobal IBS Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal IBS Treatment Market Outlook and Growth Opportunities 2026216 pages · $4,250 USDMarket Analysis & ForecastGlobal IBS Treatment Market Analysis and Forecast 2026-2032219 pages · $4,950 USD

Market perspective

The global IBS Treatment market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for IBS Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for IBS Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for IBS Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for IBS Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of IBS Treatment include Takeda Pharmaceutical Company (Japan), Nestle (Switzerland), Novartis (Switzerland), Pfizer (U.S.), Synthetic Biologics (U.S.), Synergy Pharmaceuticals (U.S.), Sucampo Pharmaceuticals (U.S.), Sebela Pharmaceuticals (Ireland) and RedHill Biopharma (Israel), etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for IBS Treatment, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of IBS Treatment, also provides the revenue of main regions and countries. Of the upcoming market potential for IBS Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the IBS Treatment revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global IBS Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for IBS Treatment revenue, projected growth trends, production technology, application and end-user industry.

IBS Treatment Segment by Company

Takeda Pharmaceutical Company (Japan)

Nestle (Switzerland)

Novartis (Switzerland)

Pfizer (U.S.)

Synthetic Biologics (U.S.)

Synergy Pharmaceuticals (U.S.)

Sucampo Pharmaceuticals (U.S.)

Sebela Pharmaceuticals (Ireland)

RedHill Biopharma (Israel)

Protagonist Therapeutics (U.S.)

Probi (Sweden)

Lexicon Pharmaceuticals (U.S.)

Ironwood Pharmaceuticals (U.S.)

Ipsen (France)

Innovate Biopharmaceuticals (U.S.)

Bausch Health

AstraZeneca (U.K)

Astellas Pharma (Japan)

Ardelyx (U.S.)

Allergan (Ireland)

Alfasigma USA (Italy)

Abbott Laboratories (U.S.)

IBS Treatment Segment by Type

IBS-D

IBS-C

IBS-M

IBS Treatment Segment by Application

Hospitals

Clinics

Research Laboratories

IBS Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global IBS Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of IBS Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of IBS Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of IBS Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of IBS Treatment company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, IBS Treatment revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global IBS Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. IBS-D Major Player Table 3. IBS-C Major Player Table 4. IBS-M Major Player Table 5. Global IBS Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Hospitals Major Player Table 7. Clinics Major Player Table 8. Research Laboratories Major Player Table 9. IBS Treatment Industry Trends Table 10. IBS Treatment Industry Drivers Table 11. IBS Treatment Industry Opportunities and Challenges Table 12. IBS Treatment Industry Restraints Table 13. Global IBS Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global IBS Treatment Market Size by Region (2021-2026) & (US$ Million) Table 15. Global IBS Treatment Market Share by Region (2021-2026) Table 16. Global IBS Treatment Market Size by Region (2027-2032) & (US$ Million) Table 17. Global IBS Treatment Market Share by Region (2027-2032) Table 18. Global IBS Treatment Revenue by Players (US$ Million) & (2021-2026) Table 19. Global IBS Treatment Revenue Market Share by Players (2021-2026) Table 20. Global IBS Treatment Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global IBS Treatment Key Players Headquarters & Area Served Table 22. Global IBS Treatment Players, Product Type & Application Table 23. Global IBS Treatment Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global IBS Treatment by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global IBS Treatment Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global IBS Treatment Revenue by Type (2021-2026) & (US$ Million) Table 28. Global IBS Treatment Revenue by Type (2027-2032) & (US$ Million) Table 29. Global IBS Treatment Revenue Market Share by Type (2021-2026) Table 30. Global IBS Treatment Revenue Market Share by Type (2027-2032) Table 31. Global IBS Treatment Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global IBS Treatment Revenue by Application (2021-2026) & (US$ Million) Table 33. Global IBS Treatment Revenue by Application (2027-2032) & (US$ Million) Table 34. Global IBS Treatment Revenue Market Share by Application (2021-2026) Table 35. Global IBS Treatment Revenue Market Share by Application (2027-2032) Table 36. Takeda Pharmaceutical Company (Japan) Company Information Table 37. Takeda Pharmaceutical Company (Japan) Business Overview Table 38. Takeda Pharmaceutical Company (Japan) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Takeda Pharmaceutical Company (Japan) IBS Treatment Product Portfolio Table 40. Takeda Pharmaceutical Company (Japan) Recent Development Table 41. Nestle (Switzerland) Company Information Table 42. Nestle (Switzerland) Business Overview Table 43. Nestle (Switzerland) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Nestle (Switzerland) IBS Treatment Product Portfolio Table 45. Nestle (Switzerland) Recent Development Table 46. Novartis (Switzerland) Company Information Table 47. Novartis (Switzerland) Business Overview Table 48. Novartis (Switzerland) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Novartis (Switzerland) IBS Treatment Product Portfolio Table 50. Novartis (Switzerland) Recent Development Table 51. Pfizer (U.S.) Company Information Table 52. Pfizer (U.S.) Business Overview Table 53. Pfizer (U.S.) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Pfizer (U.S.) IBS Treatment Product Portfolio Table 55. Pfizer (U.S.) Recent Development Table 56. Synthetic Biologics (U.S.) Company Information Table 57. Synthetic Biologics (U.S.) Business Overview Table 58. Synthetic Biologics (U.S.) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Synthetic Biologics (U.S.) IBS Treatment Product Portfolio Table 60. Synthetic Biologics (U.S.) Recent Development Table 61. Synergy Pharmaceuticals (U.S.) Company Information Table 62. Synergy Pharmaceuticals (U.S.) Business Overview Table 63. Synergy Pharmaceuticals (U.S.) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Synergy Pharmaceuticals (U.S.) IBS Treatment Product Portfolio Table 65. Synergy Pharmaceuticals (U.S.) Recent Development Table 66. Sucampo Pharmaceuticals (U.S.) Company Information Table 67. Sucampo Pharmaceuticals (U.S.) Business Overview Table 68. Sucampo Pharmaceuticals (U.S.) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Sucampo Pharmaceuticals (U.S.) IBS Treatment Product Portfolio Table 70. Sucampo Pharmaceuticals (U.S.) Recent Development Table 71. Sebela Pharmaceuticals (Ireland) Company Information Table 72. Sebela Pharmaceuticals (Ireland) Business Overview Table 73. Sebela Pharmaceuticals (Ireland) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Sebela Pharmaceuticals (Ireland) IBS Treatment Product Portfolio Table 75. Sebela Pharmaceuticals (Ireland) Recent Development Table 76. RedHill Biopharma (Israel) Company Information Table 77. RedHill Biopharma (Israel) Business Overview Table 78. RedHill Biopharma (Israel) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. RedHill Biopharma (Israel) IBS Treatment Product Portfolio Table 80. RedHill Biopharma (Israel) Recent Development Table 81. Protagonist Therapeutics (U.S.) Company Information Table 82. Protagonist Therapeutics (U.S.) Business Overview Table 83. Protagonist Therapeutics (U.S.) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Protagonist Therapeutics (U.S.) IBS Treatment Product Portfolio Table 85. Protagonist Therapeutics (U.S.) Recent Development Table 86. Probi (Sweden) Company Information Table 87. Probi (Sweden) Business Overview Table 88. Probi (Sweden) IBS Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Probi (Sweden) IBS Treatment Product Portfolio Table 90. Probi (Sweden) Recent Development Table 91. Lexicon Pharmaceuticals (U.S.) Company Information Table 92. Lexicon Pharmaceuticals (U.S.) Business Overview Table 93. Lexicon Pharmaceuticals (U.S.) IBS Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Lexicon Pharmaceuticals (U.S.) IBS Treatment Product Portfolio Table 95. Lexicon Pharmaceuticals (U.S.) Recent Development Table 96. Ironwood Pharmaceuticals (U.S.) Company Information Table 97. Ironwood Pharmaceuticals (U.S.) Business Overview Table 98. Ironwood Pharmaceuticals (U.S.) IBS Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Ironwood Pharmaceuticals (U.S.) IBS Treatment Product Portfolio Table 100. Ironwood Pharmaceuticals (U.S.) Recent Development Table 101. Ipsen (France) Company Information Table 102. Ipsen (France) Business Overview Table 103. Ipsen (France) IBS Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Ipsen (France) IBS Treatment Product Portfolio Table 105. Ipsen (France) Recent Development Table 106. Innovate Biopharmaceuticals (U.S.) Company Information Table 107. Innovate Biopharmaceuticals (U.S.) Business Overview Table 108. Innovate Biopharmaceuticals (U.S.) IBS Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Innovate Biopharmaceuticals (U.S.) IBS Treatment Product Portfolio Table 110. Innovate Biopharmaceuticals (U.S.) Recent Development Table 111. Bausch Health Company Information Table 112. Bausch Health Business Overview Table 113. Bausch Health IBS Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Bausch Health IBS Treatment Product Portfolio Table 115. Bausch Health Recent Development Table 116. AstraZeneca (U.K) Company Information Table 117. AstraZeneca (U.K) Business Overview Table 118. AstraZeneca (U.K) IBS Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. AstraZeneca (U.K) IBS Treatment Product Portfolio Table 120. AstraZeneca (U.K) Recent Development Table 121. Astellas Pharma (Japan) Company Information Table 122. Astellas Pharma (Japan) Business Overview Table 123. Astellas Pharma (Japan) IBS Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Astellas Pharma (Japan) IBS Treatment Product Portfolio Table 125. Astellas Pharma (Japan) Recent Development Table 126. Ardelyx (U.S.) Company Information Table 127. Ardelyx (U.S.) Business Overview Table 128. Ardelyx (U.S.) IBS Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Ardelyx (U.S.) IBS Treatment Product Portfolio Table 130. Ardelyx (U.S.) Recent Development Table 131. Allergan (Ireland) Company Information Table 132. Allergan (Ireland) Business Overview Table 133. Allergan (Ireland) IBS Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Allergan (Ireland) IBS Treatment Product Portfolio Table 135. Allergan (Ireland) Recent Development Table 136. Alfasigma USA (Italy) Company Information Table 137. Alfasigma USA (Italy) Business Overview Table 138. Alfasigma USA (Italy) IBS Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. Alfasigma USA (Italy) IBS Treatment Product Portfolio Table 140. Alfasigma USA (Italy) Recent Development Table 141. Abbott Laboratories (U.S.) Company Information Table 142. Abbott Laboratories (U.S.) Business Overview Table 143. Abbott Laboratories (U.S.) IBS Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 144. Abbott Laboratories (U.S.) IBS Treatment Product Portfolio Table 145. Abbott Laboratories (U.S.) Recent Development Table 146. North America IBS Treatment Revenue by Type (2021-2026) & (US$ Million) Table 147. North America IBS Treatment Revenue by Type (2027-2032) & (US$ Million) Table 148. North America IBS Treatment Revenue by Application (2021-2026) & (US$ Million) Table 149. North America IBS Treatment Revenue by Application (2027-2032) & (US$ Million) Table 150. North America IBS Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 151. North America IBS Treatment Revenue by Country (2021-2026) & (US$ Million) Table 152. North America IBS Treatment Revenue by Country (US$ Million) & (2027-2032) Table 153. Europe IBS Treatment Revenue by Type (2021-2026) & (US$ Million) Table 154. Europe IBS Treatment Revenue by Type (2027-2032) & (US$ Million) Table 155. Europe IBS Treatment Revenue by Application (2021-2026) & (US$ Million) Table 156. Europe IBS Treatment Revenue by Application (2027-2032) & (US$ Million) Table 157. Europe IBS Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 158. Europe IBS Treatment Revenue by Country (2021-2026) & (US$ Million) Table 159. Europe IBS Treatment Revenue by Country (US$ Million) & (2027-2032) Table 160. China IBS Treatment Revenue by Type (2021-2026) & (US$ Million) Table 161. China IBS Treatment Revenue by Type (2027-2032) & (US$ Million) Table 162. China IBS Treatment Revenue by Application (2021-2026) & (US$ Million) Table 163. China IBS Treatment Revenue by Application (2027-2032) & (US$ Million) Table 164. Asia IBS Treatment Revenue by Type (2021-2026) & (US$ Million) Table 165. Asia IBS Treatment Revenue by Type (2027-2032) & (US$ Million) Table 166. Asia IBS Treatment Revenue by Application (2021-2026) & (US$ Million) Table 167. Asia IBS Treatment Revenue by Application (2027-2032) & (US$ Million) Table 168. Asia IBS Treatment Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 169. Asia IBS Treatment Revenue by Region (US$ Million) & (2021-2026) Table 170. Asia IBS Treatment Revenue by Region (US$ Million) & (2027-2032) Table 171. SAMEA IBS Treatment Revenue by Type (2021-2026) & (US$ Million) Table 172. SAMEA IBS Treatment Revenue by Type (2027-2032) & (US$ Million) Table 173. SAMEA IBS Treatment Revenue by Application (2021-2026) & (US$ Million) Table 174. SAMEA IBS Treatment Revenue by Application (2027-2032) & (US$ Million) Table 175. SAMEA IBS Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 176. SAMEA IBS Treatment Revenue by Country (2021-2026) & (US$ Million) Table 177. SAMEA IBS Treatment Revenue by Country (US$ Million) & (2027-2032) Table 178. Research Programs/Design for This Report Table 179. Authors List of This Report Table 180. Secondary Sources Table 181. Primary Sources List of Figures Figure 1. IBS Treatment Image Figure 2. Global IBS Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global IBS Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 4. IBS-D Image Figure 5. IBS-C Image Figure 6. IBS-M Image Figure 7. Global IBS Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global IBS Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 9. Hospitals Image Figure 10. Clinics Image Figure 11. Research Laboratories Image Figure 12. Global IBS Treatment Market Size (US$ Million) & (2021-2032) Figure 13. Global IBS Treatment Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global IBS Treatment Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global IBS Treatment Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global IBS Treatment Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global IBS Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global IBS Treatment Revenue Market Share by Type (2021-2032) Figure 20. Global IBS Treatment Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global IBS Treatment Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global IBS Treatment Revenue Market Share by Application (2021-2032) Figure 23. North America IBS Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America IBS Treatment Revenue Share by Type (2021-2032) Figure 25. North America IBS Treatment Revenue Share by Application (2021-2032) Figure 26. North America IBS Treatment Revenue Share by Country (2021-2032) Figure 27. United States IBS Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada IBS Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico IBS Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe IBS Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe IBS Treatment Revenue Share by Type (2021-2032) Figure 32. Europe IBS Treatment Revenue Share by Application (2021-2032) Figure 33. Europe IBS Treatment Revenue Share by Country (2021-2032) Figure 34. Germany IBS Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France IBS Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. IBS Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy IBS Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain IBS Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia IBS Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands IBS Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries IBS Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China IBS Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China IBS Treatment Revenue Share by Type (2021-2032) Figure 44. China IBS Treatment Revenue Share by Application (2021-2032) Figure 45. Asia IBS Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia IBS Treatment Revenue Share by Type (2021-2032) Figure 47. Asia IBS Treatment Revenue Share by Application (2021-2032) Figure 48. Asia IBS Treatment Revenue Share by Region (2021-2032) Figure 49. Japan IBS Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea IBS Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India IBS Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia IBS Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan IBS Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia IBS Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA IBS Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA IBS Treatment Revenue Share by Type (2021-2032) Figure 57. SAMEA IBS Treatment Revenue Share by Application (2021-2032) Figure 58. SAMEA IBS Treatment Revenue Share by Country (2021-2032) Figure 59. Brazil IBS Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina IBS Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile IBS Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia IBS Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru IBS Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia IBS Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel IBS Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE IBS Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey IBS Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran IBS Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt IBS Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • IBS-D
  • IBS-C
  • IBS-M
Applications
  • Hospitals
  • Clinics
  • Research Laboratories
Companies covered
  • Takeda Pharmaceutical Company (Japan)
  • Nestle (Switzerland)
  • Novartis (Switzerland)
  • Pfizer (U.S.)
  • Synthetic Biologics (U.S.)
  • Synergy Pharmaceuticals (U.S.)
  • Sucampo Pharmaceuticals (U.S.)
  • Sebela Pharmaceuticals (Ireland)
  • RedHill Biopharma (Israel)
  • Protagonist Therapeutics (U.S.)
  • Probi (Sweden)
  • Lexicon Pharmaceuticals (U.S.)
  • Ironwood Pharmaceuticals (U.S.)
  • Ipsen (France)
  • Innovate Biopharmaceuticals (U.S.)
  • Bausch Health
  • AstraZeneca (U.K)
  • Astellas Pharma (Japan)
  • Ardelyx (U.S.)
  • Allergan (Ireland)
  • Alfasigma USA (Italy)
  • Abbott Laboratories (U.S.)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 IBS Treatment Market by Type
  3. 1.2.1 Global IBS Treatment Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 IBS-D
  5. 1.2.3 IBS-C
  6. 1.2.4 IBS-M
  7. 1.3 IBS Treatment Market by Application
  8. 1.3.1 Global IBS Treatment Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Hospitals
  10. 1.3.3 Clinics
  11. 1.3.4 Research Laboratories
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 IBS Treatment Market Dynamics
  1. 2.1 IBS Treatment Industry Trends
  2. 2.2 IBS Treatment Industry Drivers
  3. 2.3 IBS Treatment Industry Opportunities and Challenges
  4. 2.4 IBS Treatment Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global IBS Treatment Market Perspective (2021-2032)
  2. 3.2 Global IBS Treatment Growth Trends by Region
  3. 3.2.1 Global IBS Treatment Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global IBS Treatment Market Size by Region (2021-2026)
  5. 3.2.3 Global IBS Treatment Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global IBS Treatment Revenue by Players
  2. 4.1.1 Global IBS Treatment Revenue by Players (2021-2026)
  3. 4.1.2 Global IBS Treatment Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global IBS Treatment Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global IBS Treatment Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global IBS Treatment Key Players Headquarters & Area Served
  7. 4.4 Global IBS Treatment Players, Product Type & Application
  8. 4.5 Global IBS Treatment Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global IBS Treatment Market CR5 and HHI
  11. 4.6.3 2025 IBS Treatment Tier 1, Tier 2, and Tier 3
5 IBS Treatment Market Size by Type
  1. 5.1 Global IBS Treatment Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global IBS Treatment Revenue by Type (2021-2032)
  3. 5.3 Global IBS Treatment Revenue Market Share by Type (2021-2032)
6 IBS Treatment Market Size by Application
  1. 6.1 Global IBS Treatment Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global IBS Treatment Revenue by Application (2021-2032)
  3. 6.3 Global IBS Treatment Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Takeda Pharmaceutical Company (Japan)
  2. 7.1.1 Takeda Pharmaceutical Company (Japan) Company Information
  3. 7.1.2 Takeda Pharmaceutical Company (Japan) Business Overview
  4. 7.1.3 Takeda Pharmaceutical Company (Japan) IBS Treatment Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Takeda Pharmaceutical Company (Japan) IBS Treatment Product Portfolio
  6. 7.1.5 Takeda Pharmaceutical Company (Japan) Recent Developments
  7. 7.2 Nestle (Switzerland)
  8. 7.2.1 Nestle (Switzerland) Company Information
  9. 7.2.2 Nestle (Switzerland) Business Overview
  10. 7.2.3 Nestle (Switzerland) IBS Treatment Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Nestle (Switzerland) IBS Treatment Product Portfolio
  12. 7.2.5 Nestle (Switzerland) Recent Developments
  13. 7.3 Novartis (Switzerland)
  14. 7.3.1 Novartis (Switzerland) Company Information
  15. 7.3.2 Novartis (Switzerland) Business Overview
  16. 7.3.3 Novartis (Switzerland) IBS Treatment Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Novartis (Switzerland) IBS Treatment Product Portfolio
  18. 7.3.5 Novartis (Switzerland) Recent Developments
  19. 7.4 Pfizer (U.S.)
  20. 7.4.1 Pfizer (U.S.) Company Information
  21. 7.4.2 Pfizer (U.S.) Business Overview
  22. 7.4.3 Pfizer (U.S.) IBS Treatment Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Pfizer (U.S.) IBS Treatment Product Portfolio
  24. 7.4.5 Pfizer (U.S.) Recent Developments
  25. 7.5 Synthetic Biologics (U.S.)
  26. 7.5.1 Synthetic Biologics (U.S.) Company Information
  27. 7.5.2 Synthetic Biologics (U.S.) Business Overview
  28. 7.5.3 Synthetic Biologics (U.S.) IBS Treatment Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Synthetic Biologics (U.S.) IBS Treatment Product Portfolio
  30. 7.5.5 Synthetic Biologics (U.S.) Recent Developments
  31. 7.6 Synergy Pharmaceuticals (U.S.)
  32. 7.6.1 Synergy Pharmaceuticals (U.S.) Company Information
  33. 7.6.2 Synergy Pharmaceuticals (U.S.) Business Overview
  34. 7.6.3 Synergy Pharmaceuticals (U.S.) IBS Treatment Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Synergy Pharmaceuticals (U.S.) IBS Treatment Product Portfolio
  36. 7.6.5 Synergy Pharmaceuticals (U.S.) Recent Developments
  37. 7.7 Sucampo Pharmaceuticals (U.S.)
  38. 7.7.1 Sucampo Pharmaceuticals (U.S.) Company Information
  39. 7.7.2 Sucampo Pharmaceuticals (U.S.) Business Overview
  40. 7.7.3 Sucampo Pharmaceuticals (U.S.) IBS Treatment Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Sucampo Pharmaceuticals (U.S.) IBS Treatment Product Portfolio
  42. 7.7.5 Sucampo Pharmaceuticals (U.S.) Recent Developments
  43. 7.8 Sebela Pharmaceuticals (Ireland)
  44. 7.8.1 Sebela Pharmaceuticals (Ireland) Company Information
  45. 7.8.2 Sebela Pharmaceuticals (Ireland) Business Overview
  46. 7.8.3 Sebela Pharmaceuticals (Ireland) IBS Treatment Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Sebela Pharmaceuticals (Ireland) IBS Treatment Product Portfolio
  48. 7.8.5 Sebela Pharmaceuticals (Ireland) Recent Developments
  49. 7.9 RedHill Biopharma (Israel)
  50. 7.9.1 RedHill Biopharma (Israel) Company Information
  51. 7.9.2 RedHill Biopharma (Israel) Business Overview
  52. 7.9.3 RedHill Biopharma (Israel) IBS Treatment Revenue and Gross Margin (2021-2026)
  53. 7.9.4 RedHill Biopharma (Israel) IBS Treatment Product Portfolio
  54. 7.9.5 RedHill Biopharma (Israel) Recent Developments
  55. 7.10 Protagonist Therapeutics (U.S.)
  56. 7.10.1 Protagonist Therapeutics (U.S.) Company Information
  57. 7.10.2 Protagonist Therapeutics (U.S.) Business Overview
  58. 7.10.3 Protagonist Therapeutics (U.S.) IBS Treatment Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Protagonist Therapeutics (U.S.) IBS Treatment Product Portfolio
  60. 7.10.5 Protagonist Therapeutics (U.S.) Recent Developments
  61. 7.11 Probi (Sweden)
  62. 7.11.1 Probi (Sweden) Company Information
  63. 7.11.2 Probi (Sweden) Business Overview
  64. 7.11.3 Probi (Sweden) IBS Treatment Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Probi (Sweden) IBS Treatment Product Portfolio
  66. 7.11.5 Probi (Sweden) Recent Developments
  67. 7.12 Lexicon Pharmaceuticals (U.S.)
  68. 7.12.1 Lexicon Pharmaceuticals (U.S.) Company Information
  69. 7.12.2 Lexicon Pharmaceuticals (U.S.) Business Overview
  70. 7.12.3 Lexicon Pharmaceuticals (U.S.) IBS Treatment Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Lexicon Pharmaceuticals (U.S.) IBS Treatment Product Portfolio
  72. 7.12.5 Lexicon Pharmaceuticals (U.S.) Recent Developments
  73. 7.13 Ironwood Pharmaceuticals (U.S.)
  74. 7.13.1 Ironwood Pharmaceuticals (U.S.) Company Information
  75. 7.13.2 Ironwood Pharmaceuticals (U.S.) Business Overview
  76. 7.13.3 Ironwood Pharmaceuticals (U.S.) IBS Treatment Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Ironwood Pharmaceuticals (U.S.) IBS Treatment Product Portfolio
  78. 7.13.5 Ironwood Pharmaceuticals (U.S.) Recent Developments
  79. 7.14 Ipsen (France)
  80. 7.14.1 Ipsen (France) Company Information
  81. 7.14.2 Ipsen (France) Business Overview
  82. 7.14.3 Ipsen (France) IBS Treatment Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Ipsen (France) IBS Treatment Product Portfolio
  84. 7.14.5 Ipsen (France) Recent Developments
  85. 7.15 Innovate Biopharmaceuticals (U.S.)
  86. 7.15.1 Innovate Biopharmaceuticals (U.S.) Company Information
  87. 7.15.2 Innovate Biopharmaceuticals (U.S.) Business Overview
  88. 7.15.3 Innovate Biopharmaceuticals (U.S.) IBS Treatment Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Innovate Biopharmaceuticals (U.S.) IBS Treatment Product Portfolio
  90. 7.15.5 Innovate Biopharmaceuticals (U.S.) Recent Developments
  91. 7.16 Bausch Health
  92. 7.16.1 Bausch Health Company Information
  93. 7.16.2 Bausch Health Business Overview
  94. 7.16.3 Bausch Health IBS Treatment Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Bausch Health IBS Treatment Product Portfolio
  96. 7.16.5 Bausch Health Recent Developments
  97. 7.17 AstraZeneca (U.K)
  98. 7.17.1 AstraZeneca (U.K) Company Information
  99. 7.17.2 AstraZeneca (U.K) Business Overview
  100. 7.17.3 AstraZeneca (U.K) IBS Treatment Revenue and Gross Margin (2021-2026)
  101. 7.17.4 AstraZeneca (U.K) IBS Treatment Product Portfolio
  102. 7.17.5 AstraZeneca (U.K) Recent Developments
  103. 7.18 Astellas Pharma (Japan)
  104. 7.18.1 Astellas Pharma (Japan) Company Information
  105. 7.18.2 Astellas Pharma (Japan) Business Overview
  106. 7.18.3 Astellas Pharma (Japan) IBS Treatment Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Astellas Pharma (Japan) IBS Treatment Product Portfolio
  108. 7.18.5 Astellas Pharma (Japan) Recent Developments
  109. 7.19 Ardelyx (U.S.)
  110. 7.19.1 Ardelyx (U.S.) Company Information
  111. 7.19.2 Ardelyx (U.S.) Business Overview
  112. 7.19.3 Ardelyx (U.S.) IBS Treatment Revenue and Gross Margin (2021-2026)
  113. 7.19.4 Ardelyx (U.S.) IBS Treatment Product Portfolio
  114. 7.19.5 Ardelyx (U.S.) Recent Developments
  115. 7.20 Allergan (Ireland)
  116. 7.20.1 Allergan (Ireland) Company Information
  117. 7.20.2 Allergan (Ireland) Business Overview
  118. 7.20.3 Allergan (Ireland) IBS Treatment Revenue and Gross Margin (2021-2026)
  119. 7.20.4 Allergan (Ireland) IBS Treatment Product Portfolio
  120. 7.20.5 Allergan (Ireland) Recent Developments
  121. 7.21 Alfasigma USA (Italy)
  122. 7.21.1 Alfasigma USA (Italy) Company Information
  123. 7.21.2 Alfasigma USA (Italy) Business Overview
  124. 7.21.3 Alfasigma USA (Italy) IBS Treatment Revenue and Gross Margin (2021-2026)
  125. 7.21.4 Alfasigma USA (Italy) IBS Treatment Product Portfolio
  126. 7.21.5 Alfasigma USA (Italy) Recent Developments
  127. 7.22 Abbott Laboratories (U.S.)
  128. 7.22.1 Abbott Laboratories (U.S.) Company Information
  129. 7.22.2 Abbott Laboratories (U.S.) Business Overview
  130. 7.22.3 Abbott Laboratories (U.S.) IBS Treatment Revenue and Gross Margin (2021-2026)
  131. 7.22.4 Abbott Laboratories (U.S.) IBS Treatment Product Portfolio
  132. 7.22.5 Abbott Laboratories (U.S.) Recent Developments
8 North America
  1. 8.1 North America IBS Treatment Revenue (2021-2032)
  2. 8.2 North America IBS Treatment Revenue by Type (2021-2032)
  3. 8.2.1 North America IBS Treatment Revenue by Type (2021-2026)
  4. 8.2.2 North America IBS Treatment Revenue by Type (2027-2032)
  5. 8.3 North America IBS Treatment Revenue Share by Type (2021-2032)
  6. 8.4 North America IBS Treatment Revenue by Application (2021-2032)
  7. 8.4.1 North America IBS Treatment Revenue by Application (2021-2026)
  8. 8.4.2 North America IBS Treatment Revenue by Application (2027-2032)
  9. 8.5 North America IBS Treatment Revenue Share by Application (2021-2032)
  10. 8.6 North America IBS Treatment Revenue by Country
  11. 8.6.1 North America IBS Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America IBS Treatment Revenue by Country (2021-2026)
  13. 8.6.3 North America IBS Treatment Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe IBS Treatment Revenue (2021-2032)
  2. 9.2 Europe IBS Treatment Revenue by Type (2021-2032)
  3. 9.2.1 Europe IBS Treatment Revenue by Type (2021-2026)
  4. 9.2.2 Europe IBS Treatment Revenue by Type (2027-2032)
  5. 9.3 Europe IBS Treatment Revenue Share by Type (2021-2032)
  6. 9.4 Europe IBS Treatment Revenue by Application (2021-2032)
  7. 9.4.1 Europe IBS Treatment Revenue by Application (2021-2026)
  8. 9.4.2 Europe IBS Treatment Revenue by Application (2027-2032)
  9. 9.5 Europe IBS Treatment Revenue Share by Application (2021-2032)
  10. 9.6 Europe IBS Treatment Revenue by Country
  11. 9.6.1 Europe IBS Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe IBS Treatment Revenue by Country (2021-2026)
  13. 9.6.3 Europe IBS Treatment Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China IBS Treatment Revenue (2021-2032)
  2. 10.2 China IBS Treatment Revenue by Type (2021-2032)
  3. 10.2.1 China IBS Treatment Revenue by Type (2021-2026)
  4. 10.2.2 China IBS Treatment Revenue by Type (2027-2032)
  5. 10.3 China IBS Treatment Revenue Share by Type (2021-2032)
  6. 10.4 China IBS Treatment Revenue by Application (2021-2032)
  7. 10.4.1 China IBS Treatment Revenue by Application (2021-2026)
  8. 10.4.2 China IBS Treatment Revenue by Application (2027-2032)
  9. 10.5 China IBS Treatment Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia IBS Treatment Revenue (2021-2032)
  2. 11.2 Asia IBS Treatment Revenue by Type (2021-2032)
  3. 11.2.1 Asia IBS Treatment Revenue by Type (2021-2026)
  4. 11.2.2 Asia IBS Treatment Revenue by Type (2027-2032)
  5. 11.3 Asia IBS Treatment Revenue Share by Type (2021-2032)
  6. 11.4 Asia IBS Treatment Revenue by Application (2021-2032)
  7. 11.4.1 Asia IBS Treatment Revenue by Application (2021-2026)
  8. 11.4.2 Asia IBS Treatment Revenue by Application (2027-2032)
  9. 11.5 Asia IBS Treatment Revenue Share by Application (2021-2032)
  10. 11.6 Asia IBS Treatment Revenue by Country
  11. 11.6.1 Asia IBS Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia IBS Treatment Revenue by Country (2021-2026)
  13. 11.6.3 Asia IBS Treatment Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA IBS Treatment Revenue (2021-2032)
  2. 12.2 SAMEA IBS Treatment Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA IBS Treatment Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA IBS Treatment Revenue by Type (2027-2032)
  5. 12.3 SAMEA IBS Treatment Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA IBS Treatment Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA IBS Treatment Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA IBS Treatment Revenue by Application (2027-2032)
  9. 12.5 SAMEA IBS Treatment Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA IBS Treatment Revenue by Country
  11. 12.6.1 SAMEA IBS Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA IBS Treatment Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA IBS Treatment Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst